Description
Description
Round biconvex coated tablets, yellow in cross section, the core is light yellow to yellow or yellow with a greenish tint.
Release form
Film-coated tablets, 125 mg and 250 mg.
10 tablets per blister pack of polyvinyl chloride film and aluminum foil.
20 tablets per jar of low-pressure polyethylene.
1 or 2 blister packs or 1 can of polymer materials, together with instructions for
use, are placed in a pack of cardboard.
Pharmacological action
Pharmacotherapeutic group:
Antiviral.
ATX code: J05 AX
Pharmacological properties of
Pharmacodynamics. NOBASIT ® is an antiviral agent derived from isonicotinic acid. Effectively suppresses the action of influenza viruses and other pathogens of acute respiratory viral infections (ARVI) due to the direct (inhibitory) effect on the penetration of viruses through the cell membrane.
It has interferonogenic properties, increases the concentration of endogenous interferon (interferon alpha and interferon gamma) in blood plasma by 3-4 times.
Increases the body’s resistance to viral infections.
Reduces acute clinical manifestations of viral intoxication, helps to reduce the duration of the disease.
Pharmacokinetics.
After oral administration of enisamia, iodide quickly enters the bloodstream, its maximum concentration in the blood is observed 2-2.5 hours after use. Enisamia iodide and its metabolites circulate for a long time in the bloodstream (elimination half-life is 13.5-14 hours), are metabolized in the liver and are rapidly excreted from the tissues (elimination half-life is 2-3 hours).
Excreted in 90 95% with urine in the form of metabolites.
Indications
Treatment of influenza and other acute respiratory viral infections, including as part of complex therapy.
Contraindications
Hypersensitivity to any of the components of the drug.
Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Sucrose / isomaltase deficiency, fructose intolerance.
Children under 18 years of age, pregnancy, lactation.
The presence of allergic reactions, regardless of the nature of the allergen in history.
Severe organic damage to the liver and kidneys.
Use during pregnancy and lactation
Use during pregnancy and lactation is contraindicated.
Special instructions
Caution is advised to prescribe the drug to patients with thyroid disease, especially with hyperthyroidism.
Effect on the ability to drive vehicles, mechanisms
Taking NOBASIT ® does not affect the ability to drive vehicles and various mechanical equipment.
Composition of
One tablet contains:
active substance:
N-methyl-4-benzylcarbamidopyridinium iodide (enisamy iodide)
(in terms of 100% anhydrous substance) – 125 mg / 250 mg.
excipients (core):
lactose monohydrate (milk sugar) – 33.4 mg / 66.8 mg,
microcrystalline cellulose (vivapur 101) – 10.0 mg / 20.0 mg,
sucrose (refined sugar) – 9.0 mg / 18.0 mg,
povidone (low-molecular-weight polyvinylpyrrolidone medical or Plasdone K-17) – 3.6 mg / 7.2 mg,
copovidone (Plasdon S-630) – 1.4 mg / 2, 8 mg,
crospovidone (polyplasdone XL-10) – 3.8 mg / 7.6 mg,
talc – 1, 9 mg / 3.8 mg,
calcium stearate – 1.9 mg / 3.8 mg.
excipients (shell):
Aquarius Prime BAN314047 Yellow – 6 mg / 12 mg (hypromellose – 3.96 mg / 7.92 mg, titanium dioxide – 1.3437 mg / 2.6874 mg, capryl / caprylate (caprylic / capric triglyceride) – 0.54 mg / 1.08 mg, yellow iron dye – 0.042 mg / 0.084 mg, red iron oxide – 0.0003 mg / 0.0006 mg, quinoline yellow – 0.114 mg / 0.228 mg) .
Dosing and Administration
Treatment should begin when the first signs of the disease appear. If after 3 days of treatment no improvement occurs or the symptoms worsen, or new symptoms appear, you should consult your doctor. Use the drug only according to the indications the method of use and in the doses indicated in the instructions.
NOBASIT ® is taken orally after a meal, without chewing 0.5 g 3 times a day.
The maximum single dose – 1 g, daily – 2 g.
The recommended course of treatment is from 5 to 7 days.
Side effects
Allergic reactions: hypersensitivity reactions, including skin rashes, urticaria, angioedema, pruritus.
From the digestive system: dry and bitter taste in the mouth, swelling of the oral mucosa, hypersalivation, staining of the tongue yellow, nausea, vomiting, heartburn, abdominal pain, heaviness in the right hypochondrium, diarrhea, bloating.
From the respiratory system: shortness of breath, sore throat.
In the post-registration period, in isolated cases, the following adverse reactions were noted: headache, dizziness, weakness, fluctuation in blood pressure.
If you have any side effects indicated in the instructions, or are aggravated, or you notice any other side effects not listed in the instructions, inform your doctor.
Drug Interactions
Interactions with other drugs have not been adequately studied.
NOBASIT ® enhances the action of antibacterial and immunomodulating agents. It is advisable to combine this drug with ascorbic acid and other vitamins. NOBASIT ® can also be prescribed simultaneously using recombinant interferon.
If you are using the above or other medications (including over-the-counter), consult your doctor before using NOBAZIT ®.
overdose
Overdose may increase the side effects described in the appropriate section.
Gastric lavage, symptomatic treatment, is performed when they occur.
Storage Conditions
In a dry, dark place at 2 to 25 ° C.
Keep out of the reach and sight of children.
Shelf life
3 years.
Deystvuyushtee substance
nisamiya iodide
dosage form
tablets
